Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy
In conclusion, TPE may serve as a valuable and safe adjunct to corticosteroids and tocilizumab in the management of severe CRS resulting from CAR-T cell infusion. We eagerly await further prospective studies to validate this finding.PMID:38422769 | DOI:10.1016/j.intimp.2024.111761 (Source: International Immunopharmacology)
Source: International Immunopharmacology - February 29, 2024 Category: Allergy & Immunology Authors: Yedi Pu Yifan Zhao Yuekun Qi Yang Liu Meng Zhang Xia Xiao Hairong Lyu Juanxia Meng Haibo Zhu Kailin Xu Weidong Han Mingfeng Zhao Source Type: research
Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy
In conclusion, TPE may serve as a valuable and safe adjunct to corticosteroids and tocilizumab in the management of severe CRS resulting from CAR-T cell infusion. We eagerly await further prospective studies to validate this finding.PMID:38422769 | DOI:10.1016/j.intimp.2024.111761 (Source: International Immunopharmacology)
Source: International Immunopharmacology - February 29, 2024 Category: Allergy & Immunology Authors: Yedi Pu Yifan Zhao Yuekun Qi Yang Liu Meng Zhang Xia Xiao Hairong Lyu Juanxia Meng Haibo Zhu Kailin Xu Weidong Han Mingfeng Zhao Source Type: research
Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report
Pancreatic cancer (PC) is one of the most malignant tumors in digestive system due to its highly invasive and metastatic properties. At present, conventional treatment strategies for PC show the limited clinical efficacy. Therefore, novel effective therapeutic strategies are urgently needed. Here, we report a case of complete remission of advanced PC induced by claudin18.2-targeted CAR-T cell therapy. The patient was a 72-year-old man who was diagnosed with pancreatic ductal adenocarcinoma 2 years ago, and he experienced tumor recurrence and multiple metastases after pancreaticoduodenectomy and multi-line chemotherapies, i...
Source: Frontiers in Immunology - February 29, 2024 Category: Allergy & Immunology Source Type: research
Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis
Ecancermedicalscience. 2023 Dec 8;17:1644. doi: 10.3332/ecancer.2023.1644. eCollection 2023.ABSTRACTImmune checkpoint inhibitors (ICIs) are associated with specific immune-related adverse events (irAEs) which are unique compared to cytotoxic chemotherapy. For life-threatening adverse events including grade 3 or more, permanent discontinuation of the ICIs is recommended, albeit without much robust evidence. Safe re-challenge of ICIs with concurrent immunosuppression has been reported with irAEs like gastrointestinal toxicity and arthritis. Here we present a case of a lady with undifferentiated pleomorphic sarcoma with progr...
Source: Ecancermedicalscience - February 28, 2024 Category: Cancer & Oncology Authors: Chitrakshi Nagpal Sameer Rastogi Shamim A Shamim Sneha Prakash Source Type: research
Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - February 27, 2024 Category: Allergy & Immunology Authors: Jin GuoLin YangHaoming SongLi Baia Department of Cardiorespiratory Rehabilitation, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, Chinab Department of Nephrology, Shangh Source Type: research
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
Discussion: Our pre-clinical data suggest that TAK-779 is more effective than the administration of dexamethasone or the anti-IL6R therapeutic antibody tocilizumab, which brings novel therapeutic modality to TAK-779 and other CCR5 inhibitors for the treatment of virus-induced hyperinflammation syndromes, including COVID-19. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 21, 2024 Category: Drugs & Pharmacology Source Type: research
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP... (Source: Cost Effectiveness and Resource Allocation)
Source: Cost Effectiveness and Resource Allocation - February 14, 2024 Category: Health Management Authors: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi and Yazed AlRuthia Tags: Research Source Type: research
Optimal time of starting tocilizumab in acute phase of adult-onset Still ’s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature
We examined the significance of TCZ in terms of therapeutic efficacy, reduction in glucocorticoid usage, and safety in patients with AOSD.•We compared the therapeutic efficacy of TCZ with that of MTX, which is often used to treat glucocorticoid-resistant AOSD.•TCZ is undoubtedly a valuable treatment option for AOSD, especially when administered at relapse, suggesting both high safety and good efficacy. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 12, 2024 Category: Rheumatology Source Type: research
